Загрузка страницы

Acute hepatitis A to E, diagnosis and management | Thomas Berg, MD

Lecture: Acute hepatitis A to E, diagnosis and management
Speaker: Thomas Berg, MD
University Hospital Leipzig, Germany
Presented at: European Meeting on HIV & Hepatitis 2018

Learn more about European Meeting on HIV & Hepatitis that will take place from 26 May 2021 to 28 May 2021 via https://bit.ly/3wii9Nc

Founded nineteen years ago as the European HIV Resistance Workshop, the European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance has evolved to embrace all aspects of the clinical care of people living with HIV in Europe. Particular emphasis is put on optimal treatment strategies, clinical virology, molecular epidemiology, and public health aspects of HIV, HBV, HCV, and emerging viruses throughout Europe.

In the last decade, the meeting has been able to capture leading clinicians and researchers from different regions of Europe. As such, this meeting is the only European platform where HIV-treating physicians and clinical virologists get together on an annual basis to present their latest research results and discuss their clinical implications in detail.

For the Enduring Materials of the 2018 edition of the European Meeting on HIV & Hepatitis visit https://bit.ly/3ylx5Md

Registration for the 2021 webinar is open and fee is waived for healthcare professionals via this link https://bit.ly/3yq3YYj

For more medical education programs, as well as the latest scientific information, visit https://academicmedicaleducation.com/

Видео Acute hepatitis A to E, diagnosis and management | Thomas Berg, MD канала Academic Medical Education
Показать
Комментарии отсутствуют
Введите заголовок:

Введите адрес ссылки:

Введите адрес видео с YouTube:

Зарегистрируйтесь или войдите с
Информация о видео
15 марта 2021 г. 16:18:58
00:31:28
Другие видео канала
Preview: Highlights International Workshop on HIV & Women 2021 | Sharon Walmsley, FRCPC, MD, MSCPreview: Highlights International Workshop on HIV & Women 2021 | Sharon Walmsley, FRCPC, MD, MSCA new model for early clinical development of TB drugs and its application... | Norbert Heinrich, MDA new model for early clinical development of TB drugs and its application... | Norbert Heinrich, MDClinical Considerations of Aging People Living with HIV - Marta BoffitoClinical Considerations of Aging People Living with HIV - Marta BoffitoThe ABC of viral hepatitis | Mark Thursz, MRCPThe ABC of viral hepatitis | Mark Thursz, MRCPUpdates on WHO HIV Treatment Guidelines - Fujie Zhang, MD, PhDUpdates on WHO HIV Treatment Guidelines - Fujie Zhang, MD, PhDIs HCV drug resistance an issue? | Jürgen Rockstroh, MDIs HCV drug resistance an issue? | Jürgen Rockstroh, MDIs NAFLD/NASH a Public Health Challenge in 2022? - Zobair M. Younossi, MD, MPH, FACG, FACP, AGAFIs NAFLD/NASH a Public Health Challenge in 2022? - Zobair M. Younossi, MD, MPH, FACG, FACP, AGAFAntiretroviral Therapy in Pregnant Women with HIV and Neonates - Lijun SunAntiretroviral Therapy in Pregnant Women with HIV and Neonates - Lijun SunLong Acting Antivirals for Treatment and Prevention | Martin Markowitz, MDLong Acting Antivirals for Treatment and Prevention | Martin Markowitz, MDExercise and aging | Wendy Kohrt, PhDExercise and aging | Wendy Kohrt, PhDSymposium 1: ViiV - What’s New in HIV Treatment & Prevention for Youth? - Panel DiscussionSymposium 1: ViiV - What’s New in HIV Treatment & Prevention for Youth? - Panel DiscussionInvitation to join the HIV Prevention Review Meeting 2022 - 30-31 MarchInvitation to join the HIV Prevention Review Meeting 2022 - 30-31 MarchCase-Based Discussion of Oral Antivirals for COVID-19: Part 1  - Catia Marzolini, PharmD, PhDCase-Based Discussion of Oral Antivirals for COVID-19: Part 1 - Catia Marzolini, PharmD, PhDAnti-HBV potential of PD-1/PD-L1 blockade in chronic HBV infection | Daniel VerdonAnti-HBV potential of PD-1/PD-L1 blockade in chronic HBV infection | Daniel VerdonResearch into Aging with HIV: Lessons Learned and Outstanding Challenges - Peter ReissResearch into Aging with HIV: Lessons Learned and Outstanding Challenges - Peter ReissState of the Art Interventions in Improving Pediatric HIV Outcomes in OVC Programs - Grace MayanjaState of the Art Interventions in Improving Pediatric HIV Outcomes in OVC Programs - Grace MayanjaUsing Infant Animal Models to Advance Pediatric HIV Prevention, Vaccines .. | Ann Chahroudi, MD, PhDUsing Infant Animal Models to Advance Pediatric HIV Prevention, Vaccines .. | Ann Chahroudi, MD, PhDInvitation by Roger Paredes, MD, PhD | European Meeting on HIV & Hepatitis 2021Invitation by Roger Paredes, MD, PhD | European Meeting on HIV & Hepatitis 2021Differentiated & Simplified PrEP for HIV Prevention | Heather-Marie Schmidt, BMedSc (Hon), MPH, PhDDifferentiated & Simplified PrEP for HIV Prevention | Heather-Marie Schmidt, BMedSc (Hon), MPH, PhDDoes resistance still matter? | Daniel Kuritzkes, MDDoes resistance still matter? | Daniel Kuritzkes, MD
Яндекс.Метрика